Abstract

PAREDES, Kelly Muriel  and  JUELA, Christian José Corte. Importance of Tc99m-labeled MDP, DTPA, MIBI radiotracers in nuclear medicine diagnostics. Vive Rev. Salud [online]. 2023, vol.6, n.18, pp.948-960.  Epub Sep 25, 2023. ISSN 2664-3243.  https://doi.org/10.33996/revistavive.v6i18.276.

Nuclear medicine uses radiopharmaceuticals, known as radiotracers, to assess the function and metabolism of organs and body systems. Objective. To examine the relevance of technetium-99m (Tc99m)-labeled MDP, DTPA, and MIBI radiotracers in nuclear medicine diagnostics. Methodology. The PRISMA method was followed to identify studies published between 2010 and 2022. The databases consulted included Dialnet, Elsevier, Research, Redalyc, PubMed, Google Scholar and Scielo. Specific descriptors such as "Tc99m radiotracers", "MDP", "DTPA", "MIBI", and "nuclear medicine" were used, focusing the search on diagnosis and excluding therapeutic purposes. Results. Of 14 studies analyzed, there was a predominance of research on Tc99m-labeled MDP and MIBI radiotracers, focusing on diagnoses related to parathyroid lesions, hyperparathyroidism, skeletal diseases, coronary artery disease, and myocardial perfusion. Conclusions. Tc99m-labeled MDP, DTPA, and MIBI radiotracers demonstrate efficacy in a variety of diagnostic applications, including localization of parathyroid adenomas and detection of conditions such as multiple myeloma. Despite their benefits, it is crucial to continue researching and developing new radiopharmaceuticals to expand their clinical utility and further improve medical care in the field of nuclear medicine.

Keywords : Technetium Tc 99m Medronate; Technetium Tc 99m Pentetate; Technetium Tc 99m Sestamibi.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )